Xebra Brands has announced that following the issuance of a highly selective Dutch cannabis cultivation license for scientific research on June 13, 2024, its wholly owned subsidiary, Xebra Brands Europe B.V., is exploring several strategic opportunities made possible by this regulatory milestone.
The license, issued by The Minister of Health, Welfare and Sport, on behalf of the Minister, Head of the Bureau for Medicinal Cannabis, granted Xebra an Opium Exemption (for cannabis purposes) number 109230 CO/w, the right to legally cultivate and process cannabis for scientific purposes in its state of the art R&D facility built in the Village of Wilp in the Dutch province of Gelderland.
"This license marked a major milestone for our European operations," said Rodrigo Gallardo, Interim CEO of Xebra Brands. "Now, upon examination of the licensing guidelines and with the regulatory foundation in place, we are identifying the highest-value commercial and research opportunities that align with our long-term vision."
Since receiving the license, Xebra has been assessing a number of strategic opportunities to monetize this license and support a broad set of business applications.
For more information:
Xebra Brands
www.xebrabrands.com